mAb (C1); Mouse anti Human MMP2 Antibody; WB, IHC; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab115657-20μl | 20μl | In stock | $99.90 | |
| Ab115657-10μl | 10μl | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $66.90 | |
| Ab115657-50μl | 50μl | In stock | $189.90 | |
| Ab115657-100μl | 100μl | In stock | $299.90 | |
| Ab115657-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,019.90 |
mAb (C1); Mouse anti Human MMP2 Antibody; WB, IHC; Unconjugated
| Product Name | MMP2 Mouse mAb - Primary antibody, specific to MMP2, Mouse IgG1 |
|---|---|
| Synonyms | 72 kDa gelatinase; CLG4; CLG4A72 kDa type IV collagenase; collagenase type IV-A; EC 3.4.24; EC 3.4.24.24; Gelatinase A; matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IVcollagenase); matrix metalloproteinase 2 (gelatinase A, 72kD ge |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Lot by Lot |
| Host species | Mouse |
| Specificity | MMP2 |
| Immunogen | Recombinant MMP2 expressed in E.coli (AA 110-660) |
| Positive Control | WB: RAW 264.7, C6, HUVEC, A431, SK-N-SH and MCF7 cell lysates. IHC: Human kidney tissue. |
| Conjugation | Unconjugated |
| Grade | Carrier Free, ExactAb™, Validated |
| Product Description | Mouse anti Human MMP2 Antibody, Monoclonal (C1), could be used for WB, IHC and so on. Application: WB: 0.5-2µg/mL IHC: 5-20µg/mL Protein Function Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly--Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro. PEX, the C-terminal non-catalytic fragment of MMP2, posseses anti-angiogenic and anti-tumor properties and inhibits cell migration and cell adhesion to FGF2 and vitronectin. Ligand for integrinv/beta3 on the surface of blood vessels. |
| Isotype | Mouse IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 150 kDa |
| Purification Method | Protein A + Protein G purified |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -20°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at 4°C short term (1-2 weeks). Store at -20°C long term (12 months). Upon delivery aliquot. Avoid freeze/thaw cycle. |
MMP2 Mouse mAb (Ab115657) - Western Blot
All lanes: MMP2 Mouse mAb (Ab115657) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Mouse IgG H&L (HRP) (Ab138040) at 1/30000 dilution
Predicted band size: 74 kDa
Observed band size: 74 kDa
Exposure time: 29.4 s
MMP2 Mouse mAb (Ab115657) - IHC
DAB staining on IHC
Samples: Human Kidney Tissue
Primary Ab: 20 µg/mL MMP2 Mouse mAb (Ab115657)
Second Ab: 2 µg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Application | Dilution info |
|---|---|
| IHC | 5-20 µg/mL |
| WB | 0.5-2µg/mL |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1201918 | Certificate of Analysis | Dec 06, 2023 | Ab115657 |
| ZJ23F1201919 | Certificate of Analysis | Dec 06, 2023 | Ab115657 |
| ZJ23F1201920 | Certificate of Analysis | Dec 06, 2023 | Ab115657 |
| 1. DasGupta S, Murumkar PR, Giridhar R, Yadav MR. (2009) Current perspective of TACE inhibitors: a review.. Bioorg Med Chem, 17 (2): (444-59). [PMID:19095454] |
| 2. Wu Y, Li J, Wu J, Morgan P, Xu X, Rancati F, Vallese S, Raveglia L, Hotchandani R, Fuller N et al.. (2012) Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).. Bioorg Med Chem Lett, 22 (1): (138-43). [PMID:22153340] |
| 3. De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J et al.. (2011) Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.. Bioorg Med Chem Lett, 21 (11): (3301-6). [PMID:21536437] |
| 4. Jin Y, Roycik MD, Bosco DB, Cao Q, Constantino MH, Schwartz MA, Sang QX. (2013) Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.. J Med Chem, 56 (11): (4357-73). [PMID:23631440] |
| 5. Johnson AR, Pavlovsky AG, Ortwine DF, Prior F, Man CF, Bornemeier DA, Banotai CA, Mueller WT, McConnell P, Yan C et al.. (2007) Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.. J Biol Chem, 282 (38): (27781-91). [PMID:17623656] |
| 6. Georgiadis D, Yiotakis A. (2008) Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.. Bioorg Med Chem, 16 (19): (8781-94). [PMID:18790648] |
| 7. Kwan JC, Eksioglu EA, Liu C, Paul VJ, Luesch H. (2009) Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.. J Med Chem, 52 (18): (5732-47). [PMID:19715320] |
| 8. Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E et al.. (2011) Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.. Eur J Med Chem, 46 (7): (2617-29). [PMID:21514700] |
| 9. Ruminski PG, Massa M, Strohbach J, Hanau CE, Schmidt M, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Shieh HS et al.. (2016) Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.. J Med Chem, 59 (1): (313-27). [PMID:26653735] |
| 10. Jennifer A Jacobsen,Jessica L Fullagar,Melissa T Miller,Seth M Cohen. (2010-12-30) Identifying chelators for metalloprotein inhibitors using a fragment-based approach.. Journal of medicinal chemistry, 54 ((2)): (591-602). [PMID:21189019] |
| 11. Major Gooyit,Wei Song,Kiran V Mahasenan,Katerina Lichtenwalter,Mark A Suckow,Valerie A Schroeder,William R Wolter,Shahriar Mobashery,Mayland Chang. (2013-09-14) O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.. Journal of medicinal chemistry, 56 ((20)): (8139-8150). [PMID:24028490] |
| 12. Anna M Knapinska,Daniela Dreymuller,Andreas Ludwig,Lyndsay Smith,Vladislav Golubkov,Anjum Sohail,Rafael Fridman,Marc Giulianotti,Travis M LaVoi,Richard A Houghten,Gregg B Fields,Dmitriy Minond. (2015-07-21) SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.. Journal of medicinal chemistry, 58 ((15)): (5808-5824). [PMID:26192023] |
| 13. Pikul S, Dunham KM, Almstead NG, De B, Natchus MG, Taiwo YO, Williams LE, Hynd BA, Hsieh LC, Janusz MJ, Gu F, Mieling GE.. (2001) Heterocycle-based MMP inhibitors with P2' substituents.. Bioorg Med Chem Lett, 11 (8): (1009-1013). [PMID:11327577] |
| 14. Ishida K, Simizu S, Teruya T, Wierzba MK, Osada H.. (2004) Rational design and synthesis of novel heparan sulfate mimetic compounds as antiadhesive agents.. Bioorg Med Chem Lett, 14 (10): (2505-2509). [PMID:15109641] |
| 15. Esser CK, Bugianesi RL, Caldwell CG, Chapman KT, Durette PL, Girotra NN, Kopka IE, Lanza TJ, Levorse DA, MacCoss M, Owens KA, Ponpipom MM, Simeone JP, Harrison RK, Niedzwiecki L, Becker JW, Marcy AI, Axel MG, Christen AJ, McDonnell J, Moore VL, Olszewski JM, Saphos C, Visco DM, Hagmann WK.. (1997) Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.. J Med Chem, 40 (6): (1026-1040). [PMID:9083493] |
| 16. Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Mieling GE.. (1999) Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.. J Med Chem, 42 (1): (87-94). [PMID:9888835] |
| 17. Cheng M, De B, Almstead NG, Pikul S, Dowty ME, Dietsch CR, Dunaway CM, Gu F, Hsieh LC, Janusz MJ, Taiwo YO, Natchus MG, Hudlicky T, Mandel M.. (1999) Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.. J Med Chem, 42 (26): (5426-5436). [PMID:10639284] |
| 18. Natchus MG, Bookland RG, Laufersweiler MJ, Pikul S, Almstead NG, De B, Janusz MJ, Hsieh LC, Gu F, Pokross ME, Patel VS, Garver SM, Peng SX, Branch TM, King SL, Baker TR, Foltz DJ, Mieling GE.. (2001) Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines.. J Med Chem, 44 (7): (1060-1071). [PMID:11297453] |
| 19. Breuer E, Salomon CJ, Katz Y, Chen W, Lu S, Röschenthaler GV, Hadar R, Reich R.. (2004) Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.. J Med Chem, 47 (11): (2826-2832). [PMID:15139760] |
| 20. Rizzo RC, Toba S, Kuntz ID.. (2004) A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics simulations.. J Med Chem, 47 (12): (3065-3074). [PMID:15163188] |
| 21. Xiang JS, Hu Y, Rush TS, Thomason JR, Ipek M, Sum PE, Abrous L, Sabatini JJ, Georgiadis K, Reifenberg E, Majumdar M, Morris EA, Tam S.. (2006) Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors.. Bioorg Med Chem Lett, 16 (2): (311-316). [PMID:16275085] |
| 22. Campestre C, Agamennone M, Tortorella P, Preziuso S, Biasone A, Gavuzzo E, Pochetti G, Mazza F, Hiller O, Tschesche H, Consalvi V, Gallina C.. (2006) N-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: mode of binding in a complex with MMP-8.. Bioorg Med Chem Lett, 16 (1): (20-24). [PMID:16242329] |
| 23. Pochetti G, Gavuzzo E, Campestre C, Agamennone M, Tortorella P, Consalvi V, Gallina C, Hiller O, Tschesche H, Tucker PA, Mazza F.. (2006) Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates.. J Med Chem, 49 (3): (923-931). [PMID:16451058] |
| 24. Santos MA, Enyedy EA, Nuti E, Rossello A, Krupenko NI, Krupenko SA.. (2007) Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.. Bioorg Med Chem, 15 (3): (1266-1274). [PMID:17127067] |
| 25. Yang SM, Scannevin RH, Wang B, Burke SL, Huang Z, Karnachi P, Wilson LJ, Rhodes KJ, Lagu B, Murray WV.. (2008) beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.. Bioorg Med Chem Lett, 18 (3): (1140-1145). [PMID:18083558] |
| 26. Li JJ, Nahra J, Johnson AR, Bunker A, O'Brien P, Yue WS, Ortwine DF, Man CF, Baragi V, Kilgore K, Dyer RD, Han HK.. (2008) Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.. J Med Chem, 51 (4): (835-841). [PMID:18251495] |
| 27. Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodes KJ, Jackson PF.. (2008) 1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.. Bioorg Med Chem Lett, 18 (1): (409-413). [PMID:17981034] |
| 28. Lo PC, Chen J, Stefflova K, Warren MS, Navab R, Bandarchi B, Mullins S, Tsao M, Cheng JD, Zheng G.. (2009) Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers.. J Med Chem, 52 (2): (358-368). [PMID:19093877] |
| 29. Balas L, Durand T, Saha S, Johnson I, Mukhopadhyay S.. (2009) Total synthesis of photoactivatable or fluorescent anandamide probes: novel bioactive compounds with angiogenic activity.. J Med Chem, 52 (4): (1005-1017). [PMID:19161308] |
| 30. Lauer-Fields JL, Minond D, Chase PS, Baillargeon PE, Saldanha SA, Stawikowska R, Hodder P, Fields GB.. (2009) High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.. Bioorg Med Chem, 17 (3): (990-1005). [PMID:18358729] |
| 31. Yan YL, Miller MT, Cao Y, Cohen SM.. (2009) Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.. Bioorg Med Chem Lett, 19 (7): (1970-1976). [PMID:19261472] |
| 32. Monovich LG, Tommasi RA, Fujimoto RA, Blancuzzi V, Clark K, Cornell WD, Doti R, Doughty J, Fang J, Farley D, Fitt J, Ganu V, Goldberg R, Goldstein R, Lavoie S, Kulathila R, Macchia W, Parker DT, Melton R, O'Byrne E, Pastor G, Pellas T, Quadros E, Reel N, Roland DM, Sakane Y, Singh H, Skiles J, Somers J, Toscano K, Wigg A, Zhou S, Zhu L, Shieh WC, Xue S, McQuire LW.. (2009) Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.. J Med Chem, 52 (11): (3523-3538). [PMID:19422229] |
| 33. Hopper DW, Vera MD, How D, Sabatini J, Xiang JS, Ipek M, Thomason J, Hu Y, Feyfant E, Wang Q, Georgiadis KE, Reifenberg E, Sheldon RT, Keohan CC, Majumdar MK, Morris EA, Skotnicki J, Sum PE.. (2009) Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitors.. Bioorg Med Chem Lett, 19 (9): (2487-2491). [PMID:19329309] |
| 34. Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A.. (2009) N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.. J Med Chem, 52 (15): (4757-4773). [PMID:19606871] |
| 35. Johnson SL, Chen LH, Barile E, Emdadi A, Sabet M, Yuan H, Wei J, Guiney D, Pellecchia M.. (2009) Structure-activity relationship studies of a novel series of anthrax lethal factor inhibitors.. Bioorg Med Chem, 17 (9): (3352-3368). [PMID:19359184] |
| 36. Li W, Li J, Wu Y, Rancati F, Vallese S, Raveglia L, Wu J, Hotchandani R, Fuller N, Cunningham K, Morgan P, Fish S, Krykbaev R, Xu X, Tam S, Goldman SJ, Abraham W, Williams C, Sypek J, Mansour TS.. (2009) Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.. J Med Chem, 52 (17): (5408-5419). [PMID:19725580] |
| 37. Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D'Amelio N, Maiocchi A, Uggeri F, Rossello A.. (2009) Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.. J Med Chem, 52 (20): (6347-6361). [PMID:19775099] |
| 38. Capková K, Hixon MS, Pellett S, Barbieri JT, Johnson EA, Janda KD.. (2010) Benzylidene cyclopentenediones: First irreversible inhibitors against botulinum neurotoxin A's zinc endopeptidase.. Bioorg Med Chem Lett, 20 (1): (206-208). [PMID:19914829] |
| 39. Ma Y, Nam S, Jove R, Yakushijin K, Horne DA.. (2010) Synthesis and anticancer activities of ageladine A and structural analogs.. Bioorg Med Chem Lett, 20 (1): (83-86). [PMID:19948404] |
| 40. Schnute ME, O'Brien PM, Nahra J, Morris M, Howard Roark W, Hanau CE, Ruminski PG, Scholten JA, Fletcher TR, Hamper BC, Carroll JN, Patt WC, Shieh HS, Collins B, Pavlovsky AG, Palmquist KE, Aston KW, Hitchcock J, Rogers MD, McDonald J, Johnson AR, Munie GE, Wittwer AJ, Man CF, Settle SL, Nemirovskiy O, Vickery LE, Agawal A, Dyer RD, Sunyer T.. (2010) Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.. Bioorg Med Chem Lett, 20 (2): (576-580). [PMID:20005097] |
| 41. Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A.. (2010) Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.. J Med Chem, 53 (6): (2622-2635). [PMID:20180536] |
| 42. Testero SA, Lee M, Staran RT, Espahbodi M, Llarrull LI, Toth M, Mobashery S, Chang M.. (2011) Sulfonate-containing thiiranes as selective gelatinase inhibitors.. ACS Med Chem Lett, 2 (2): (177-181). [PMID:24900296] |
| 43. De Savi C, Pape A, Cumming JG, Ting A, Smith PD, Burrows JN, Mills M, Davies C, Lamont S, Milne D, Cook C, Moore P, Sawyer Y, Gerhardt S.. (2011) The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.. Bioorg Med Chem Lett, 21 (5): (1376-1381). [PMID:21300546] |
| 44. Gooyit M, Lee M, Schroeder VA, Ikejiri M, Suckow MA, Mobashery S, Chang M.. (2011) Selective water-soluble gelatinase inhibitor prodrugs.. J Med Chem, 54 (19): (6676-6690). [PMID:21866961] |
| 45. La Pietra V, Marinelli L, Cosconati S, Di Leva FS, Nuti E, Santamaria S, Pugliesi I, Morelli M, Casalini F, Rossello A, La Motta C, Taliani S, Visse R, Nagase H, da Settimo F, Novellino E.. (2012) Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.. Eur J Med Chem, 47 (143-152). [PMID:22088955] |
| 46. Li B, Cardinale SC, Butler MM, Pai R, Nuss JE, Peet NP, Bavari S, Bowlin TL.. (2011) Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.. Bioorg Med Chem, 19 (24): (7338-7348). [PMID:22082667] |
| 47. Roth J, Minond D, Darout E, Liu Q, Lauer J, Hodder P, Fields GB, Roush WR.. (2011) Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.. Bioorg Med Chem Lett, 21 (23): (7180-7184). [PMID:22018790] |
| 48. De Savi C, Morley AD, Nash I, Karoutchi G, Page K, Ting A, Gerhardt S.. (2012) Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.. Bioorg Med Chem Lett, 22 (1): (271-277). [PMID:22153941] |
| 49. Topai A, Breccia P, Minissi F, Padova A, Marini S, Cerbara I.. (2012) In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.. Bioorg Med Chem, 20 (7): (2323-2337). [PMID:22386984] |
| 50. Gege C, Bao B, Bluhm H, Boer J, Gallagher BM, Korniski B, Powers TS, Steeneck C, Taveras AG, Baragi VM.. (2012) Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.. J Med Chem, 55 (2): (709-716). [PMID:22175799] |
| 51. Lee M, Ikejiri M, Klimpel D, Toth M, Espahbodi M, Hesek D, Forbes C, Kumarasiri M, Noll BC, Chang M, Mobashery S.. (2012) Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.. ACS Med Chem Lett, 3 (6): (490-495). [PMID:22737278] |
| 52. Abdul-Hay SO, Lane AL, Caulfield TR, Claussin C, Bertrand J, Masson A, Choudhry S, Fauq AH, Maharvi GM, Leissring MA.. (2013) Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity.. J Med Chem, 56 (6): (2246-2255). [PMID:23437776] |
| 53. Salvador LA, Taori K, Biggs JS, Jakoncic J, Ostrov DA, Paul VJ, Luesch H.. (2013) Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells.. J Med Chem, 56 (3): (1276-1290). [PMID:23350733] |
| 54. Nuti E, Santamaria S, Casalini F, Yamamoto K, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Marini AM, Salerno S, Taliani S, Da Settimo F, Nagase H, Rossello A.. (2013) Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.. Eur J Med Chem, 62 (379-394). [PMID:23376997] |
| 55. Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A.. (2013) Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.. J Med Chem, 56 (20): (8089-8103). [PMID:24044434] |
| 56. Maingot L, Elbakali J, Dumont J, Bosc D, Cousaert N, Urban A, Deglane G, Villoutreix B, Nagase H, Sperandio O, Leroux F, Deprez B, Deprez-Poulain R.. (2013) Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group.. Eur J Med Chem, 69 (244-261). [PMID:24044937] |
| 57. Day JA, Cohen SM.. (2013) Investigating the selectivity of metalloenzyme inhibitors.. J Med Chem, 56 (20): (7997-8007). [PMID:24074025] |
| 58. Sodji QH, Patil V, Kornacki JR, Mrksich M, Oyelere AK.. (2013) Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.. J Med Chem, 56 (24): (9969-9981). [PMID:24304348] |
| 59. Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M.. (2014) Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.. J Med Chem, 57 (21): (8886-8902). [PMID:25264600] |
| 60. Spicer TP, Jiang J, Taylor AB, Choi JY, Hart PJ, Roush WR, Fields GB, Hodder PS, Minond D.. (2014) Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.. J Med Chem, 57 (22): (9598-9611). [PMID:25330343] |
| 61. Durham TB, Klimkowski VJ, Rito CJ, Marimuthu J, Toth JL, Liu C, Durbin JD, Stout SL, Adams L, Swearingen C, Lin C, Chambers MG, Thirunavukkarasu K, Wiley MR.. (2014) Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.. J Med Chem, 57 (24): (10476-10485). [PMID:25415648] |
| 62. Matusiak N, Castelli R, Tuin AW, Overkleeft HS, Wisastra R, Dekker FJ, Prély LM, Bischoff R, van Waarde A, Dierckx RA, Elsinga PH.. (2015) A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹⁸F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.. Bioorg Med Chem, 23 (1): (192-202). [PMID:25438884] |
| 63. Tseng CH, Tzeng CC, Chiu CC, Hsu CY, Chou CK, Chen YL.. (2015) Discovery of 2-[2-(5-nitrofuran-2-yl)vinyl]quinoline derivatives as a novel type of antimetastatic agents.. Bioorg Med Chem, 23 (1): (141-148). [PMID:25467291] |
| 64. Behrends M, Wagner S, Kopka K, Schober O, Schäfers M, Kumbhar S, Waller M, Haufe G.. (2015) New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids.. Bioorg Med Chem, 23 (13): (3809-3818). [PMID:25921268] |
| 65. Camodeca C, Nuti E, Tepshi L, Boero S, Tuccinardi T, Stura EA, Poggi A, Zocchi MR, Rossello A.. (2016) Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.. Eur J Med Chem, 111 (193-201). [PMID:26871660] |
| 66. Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T.. (2016) Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.. Bioorg Med Chem, 24 (18): (4291-4309). [PMID:27452283] |
| 67. Nara H, Sato K, Kaieda A, Oki H, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M.. (2016) Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.. Bioorg Med Chem, 24 (23): (6149-6165). [PMID:27825552] |
| 68. Durham TB, Marimuthu J, Toth JL, Liu C, Adams L, Mudra DR, Swearingen C, Lin C, Chambers MG, Thirunavukkarasu K, Wiley MR.. (2017) A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose.. J Med Chem, 60 (13): (5933-5939). [PMID:28613895] |
| 69. Choi JY, Fuerst R, Knapinska AM, Taylor AB, Smith L, Cao X, Hart PJ, Fields GB, Roush WR.. (2017) Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.. J Med Chem, 60 (13): (5816-5825). [PMID:28653849] |
| 70. Ramsbeck D, Hamann A, Schlenzig D, Schilling S, Buchholz M.. (2017) First insight into structure-activity relationships of selective meprin β inhibitors.. Bioorg Med Chem Lett, 27 (11): (2428-2431). [PMID:28408220] |
| 71. Chen AY, Thomas PW, Stewart AC, Bergstrom A, Cheng Z, Miller C, Bethel CR, Marshall SH, Credille CV, Riley CL, Page RC, Bonomo RA, Crowder MW, Tierney DL, Fast W, Cohen SM.. (2017) Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.. J Med Chem, 60 (17): (7267-7283). [PMID:28809565] |
| 72. Li X, Peterson YK, Inks ES, Himes RA, Li J, Zhang Y, Kong X, Chou CJ.. (2018) Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.. J Med Chem, 61 (6): (2589-2603). [PMID:29499113] |
| 73. Senn N, Ott M, Lanz J, Riedl R.. (2017) Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.. J Med Chem, 60 (23): (9585-9598). [PMID:28953404] |
| 74. Lim WC, Kim H, Kim YJ, Choi KC, Lee IH, Lee KH, Kim MK, Ko H.. (2017) Dioscin suppresses TGF-β1-induced epithelial-mesenchymal transition and suppresses A549 lung cancer migration and invasion.. Bioorg Med Chem Lett, 27 (15): (3342-3348). [PMID:28610976] |
| 75. Perez C, Li J, Parlati F, Rouffet M, Ma Y, Mackinnon AL, Chou TF, Deshaies RJ, Cohen SM.. (2017) Discovery of an Inhibitor of the Proteasome Subunit Rpn11.. J Med Chem, 60 (4): (1343-1361). [PMID:28191850] |
| 76. Fuerst R, Yong Choi J, Knapinska AM, Smith L, Cameron MD, Ruiz C, Fields GB, Roush WR.. (2018) Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.. Bioorg Med Chem, 26 (18): (4984-4995). [PMID:30249495] |
| 77. Credille CV, Dick BL, Morrison CN, Stokes RW, Adamek RN, Wu NC, Wilson IA, Cohen SM.. (2018) Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.. J Med Chem, 61 (22): (10206-10217). [PMID:30351002] |
| 78. Boiteau JG, Ouvry G, Arlabosse JM, Astri S, Beillard A, Bhurruth-Alcor Y, Bonnary L, Bouix-Peter C, Bouquet K, Bourotte M, Cardinaud I, Comino C, Deprez B, Duvert D, Féret A, Hacini-Rachinel F, Harris CS, Luzy AP, Mathieu A, Millois C, Orsini N, Pascau J, Pinto A, Piwnica D, Polge G, Reitz A, Reversé K, Rodeville N, Rossio P, Spiesse D, Tabet S, Taquet N, Tomas L, Vial E, Hennequin LF.. (2018) Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.. Bioorg Med Chem, 26 (4): (945-956). [PMID:28818461] |
| 79. Wang CG, Yao WN, Zhang B, Hua J, Liang D, Wang HS.. (2018) Lung cancer and matrix metalloproteinases inhibitors of polyphenols from Selaginella tamariscina with suppression activity of migration.. Bioorg Med Chem Lett, 28 (14): (2413-2417). [PMID:29921475] |
| 80. Kumar D, Gupta SK, Ganeshpurkar A, Gutti G, Krishnamurthy S, Modi G, Singh SK.. (2018) Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease.. Eur J Med Chem, 150 (87-101). [PMID:29524731] |
| 81. Stallivieri A, Colombeau L, Devy J, Etique N, Chaintreuil C, Myrzakhmetov B, Achard M, Baros F, Arnoux P, Vanderesse R, Frochot C.. (2018) New photodynamic molecular beacons (PMB) as potential cancer-targeted agents in PDT.. Bioorg Med Chem, 26 (3): (688-702). [PMID:29338907] |
| 82. Galibert M, Wartenberg M, Lecaille F, Saidi A, Mavel S, Joulin-Giet A, Korkmaz B, Brömme D, Aucagne V, Delmas AF, Lalmanach G.. (2018) Substrate-derived triazolo- and azapeptides as inhibitors of cathepsins K and S.. Eur J Med Chem, 144 (201-210). [PMID:29272750] |
| 83. Zheng D, Han L, Qu X, Chen X, Zhong J, Bi X, Liu J, Jiang Y, Jiang C, Huang X.. (2017) Cytotoxic Fusicoccane-Type Diterpenoids from Streptomyces violascens Isolated from Ailuropoda melanoleuca Feces.. J Nat Prod, 80 (4): (837-844). [PMID:28206772] |
| 84. Liu B, Trout REL, Chu GH, McGarry D, Jackson RW, Hamrick JC, Daigle DM, Cusick SM, Pozzi C, De Luca F, Benvenuti M, Mangani S, Docquier JD, Weiss WJ, Pevear DC, Xerri L, Burns CJ.. (2020) Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.. J Med Chem, 63 (6): (2789-2801). [PMID:31765155] |
| 85. Jung O, Lee J, Lee YJ, Yun JM, Son YJ, Cho JY, Ryou C, Lee SY.. (2016) Timosaponin AIII inhibits migration and invasion of A549 human non-small-cell lung cancer cells via attenuations of MMP-2 and MMP-9 by inhibitions of ERK1/2, Src/FAK and β-catenin signaling pathways.. Bioorg Med Chem Lett, 26 (16): (3963-3967). [PMID:27422337] |
| 86. Gona K,Toczek J,Ye Y,Sanzida N,Golbazi A,Boodagh P,Salarian M,Jung JJ,Rajendran S,Kukreja G,Wu TL,Devel L,Sadeghi MM. (2020) Hydroxamate-Based Selective Macrophage Elastase (MMP-12) Inhibitors and Radiotracers for Molecular Imaging.. J Med Chem, 63 (23): (15037-15049). [PMID:33206510] |
| 87. Rocchi D,Blázquez-Barbadillo C,Agamennone M,Laghezza A,Tortorella P,Vicente-Zurdo D,Rosales-Conrado N,Moyano P,Pino JD,González JF,Menéndez JC. (2021) Discovery of 7-aminophenanthridin-6-one as a new scaffold for matrix metalloproteinase inhibitors with multitarget neuroprotective activity.. Eur J Med Chem, 210 (113061-113061). [PMID:33310289] |
| 88. Lenci E,Angeli A,Calugi L,Innocenti R,Carta F,Supuran CT,Trabocchi A. (2021) Multitargeting application of proline-derived peptidomimetics addressing cancer-related human matrix metalloproteinase 9 and carbonic anhydrase II.. Eur J Med Chem, 214 (113260-113260). [PMID:33581552] |
| 89. Stetler-Stevenson, W G WG, Krutzsch, H C HC and Liotta, L A LA.. (1992) TIMP-2: identification and characterization of a new member of the metalloproteinase inhibitor family.. Matrix (Stuttgart, Germany). Supplement, [PMID:1480041] |
| 90. Collier, I E IE, Bruns, G A GA, Goldberg, G I GI and Gerhard, D S DS.. (1991) On the structure and chromosome location of the 72- and 92-kDa human type IV collagenase genes.. Genomics, [PMID:1851724] |
| 91. Huhtala, P P and 5 more authors.. (1990) Completion of the primary structure of the human type IV collagenase preproenzyme and assignment of the gene (CLG4) to the q21 region of chromosome 16.. Genomics, [PMID:2158484] |
| 92. Huhtala, P P, Chow, L T LT and Tryggvason, K K.. (1990) Structure of the human type IV collagenase gene.. The Journal of biological chemistry, (5): [PMID:2162831] |
| 93. Collier, I E IE and 9 more authors.. (1988) H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen.. The Journal of biological chemistry, (15): [PMID:2834383] |
| 94. Libson, A M AM and 5 more authors.. (1995) Crystal structure of the haemopexin-like C-terminal domain of gelatinase A.. Nature structural biology, [PMID:7583664] |
| 95. Gohlke, U U and 5 more authors.. (1996) The C-terminal (haemopexin-like) domain structure of human gelatinase A (MMP2): structural implications for its function.. FEBS letters, (8): [PMID:8549817] |
| 96. Butler, G S GS, Will, H H, Atkinson, S J SJ and Murphy, G G.. (1997) Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases.. European journal of biochemistry, (1): [PMID:9119036] |
| 97. Brooks, P C PC, Silletti, S S, von Schalscha, T L TL, Friedlander, M M and Cheresh, D A DA.. (1998) Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity.. Cell, (6): [PMID:9476898] |
| 98. Prontera, C C, Mariani, B B, Rossi, C C, Poggi, A A and Rotilio, D D.. (1999) Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.. International journal of cancer, (31): [PMID:10328230] |
| 99. Morgunova, E E and 6 more authors.. (1999) Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed.. Science (New York, N.Y.), (4): [PMID:10356396] |
| 100. Treharne, G D GD and 5 more authors.. (1999) Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease.. The British journal of surgery, [PMID:10460642] |
| 101. Gusman, H H and 5 more authors.. (2001) Salivary histatin 5 is an inhibitor of both host and bacterial enzymes implicated in periodontal disease.. Infection and immunity, [PMID:11179305] |
| 102. Martignetti, J A JA and 13 more authors.. (2001) Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome.. Nature genetics, [PMID:11431697] |
| 103. Bello, L L and 12 more authors.. (2001) Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2.. Cancer research, (15): [PMID:11751392] |
| 104. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ.. (2002) TTD: Therapeutic Target Database.. Nucleic acids research, (1): [PMID:11752352] |
| 105. Gehrmann, Marion M, Briknarová, Klára K, Bányai, László L, Patthy, László L and Llinás, Miguel M.. (2002) The col-1 module of human matrix metalloproteinase-2 (MMP-2): structural/functional relatedness between gelatin-binding fibronectin type II modules and lysine-binding kringle domains.. Biological chemistry, [PMID:11928808] |
| 106. Morgunova, Ekaterina E, Tuuttila, Ari A, Bergmann, Ulrich U and Tryggvason, Karl K.. (2002) Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2.. Proceedings of the National Academy of Sciences of the United States of America, (28): [PMID:12032297] |
| 107. Feng, Yiqing Y and 11 more authors.. (2002) Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor.. Biochimica et biophysica acta, (29): [PMID:12147339] |
| 108. Reinhardt, D D and 5 more authors.. (2002) Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP.. Heart (British Cardiac Society), [PMID:12381651] |
| 109. Noda, Kousuke K and 6 more authors.. (2003) Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy.. Investigative ophthalmology & visual science, [PMID:12714657] |
| 110. Takino, Takahisa T and 7 more authors.. (2003) Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases.. Oncogene, (24): [PMID:12879005] |
| 111. Zhang, Yuhua Y and 19 more authors.. (2004) Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.. The Journal of pharmacology and experimental therapeutics, [PMID:14718605] |
| 112. Martin, Joel J and 121 more authors.. (2004) The sequence and analysis of duplication-rich human chromosome 16.. Nature, (23): [PMID:15616553] |
| 113. Zankl, A A, Bonafé, L L, Calcaterra, V V, Di Rocco, M M and Superti-Furga, A A.. (2005) Winchester syndrome caused by a homozygous mutation affecting the active site of matrix metalloproteinase 2.. Clinical genetics, [PMID:15691365] |
| 114. Williams, R N RN, Parsons, S L SL, Morris, T M TM, Rowlands, B J BJ and Watson, S A SA.. (2005) Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, [PMID:15993560] |
| 115. Becker, Daniel P DP and 17 more authors.. (2005) Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.. Journal of medicinal chemistry, (20): [PMID:16220987] |
| 116. Rouzier, C C and 6 more authors.. (2006) A novel homozygous MMP2 mutation in a family with Winchester syndrome.. Clinical genetics, [PMID:16542393] |
| 117. Sjöblom, Tobias T and 28 more authors.. (2006) The consensus coding sequences of human breast and colorectal cancers.. Science (New York, N.Y.), (13): [PMID:16959974] |
| 118. Sariahmetoglu, Meltem M and 10 more authors.. (2007) Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, [PMID:17435175] |
| 119. Forbes, Christopher C and 9 more authors.. (2009) Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases.. Chemical biology & drug design, [PMID:19807733] |
| 120. Radichev, Ilian A IA and 6 more authors.. (2010) Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase.. The Journal of biological chemistry, (21): [PMID:20308072] |
| 121. Durrant, Jacob D JD, de Oliveira, César A F CA and McCammon, J Andrew JA.. (2011) Pyrone-based inhibitors of metalloproteinase types 2 and 3 may work as conformation-selective inhibitors.. Chemical biology & drug design, [PMID:21609408] |
| 122. Hashimoto, Hiroshi H and 5 more authors.. (2011) Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of β-amyloid precursor protein-derived inhibitor.. The Journal of biological chemistry, (23): [PMID:21813640] |
| 123. Lovett, David H DH and 6 more authors.. (2012) A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity.. PloS one, [PMID:22509276] |
| 124. Rosenow, Anja A and 6 more authors.. (2012) Resveratrol-induced changes of the human adipocyte secretion profile.. Journal of proteome research, (7): [PMID:22905912] |
| 125. Li, Jing J and 21 more authors.. (2017) Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.. Nature chemical biology, [PMID:28244987] |
